- Home
- DBL vs ALEC Comparison
DBL vs ALEC Comparison
Compare DBL & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | ALEC |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 275.8M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DBL | ALEC |
|---|---|---|
| Price | $13.51 | $2.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 141.0K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $850.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.56 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.94 | $1.09 |
| 52 Week High | $15.56 | $2.76 |
Technical Indicators
Market Signals| Indicator | DBL | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 69.08 |
| Support Level | $12.94 | $1.87 |
| Resistance Level | $14.40 | N/A |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 9.08 | 87.05 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.